MARKET

LNTH

LNTH

Lantheus Hldg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.97
-0.04
-0.15%
After Hours: 26.97 0 0.00% 16:01 09/24 EDT
OPEN
26.80
PREV CLOSE
27.01
HIGH
27.17
LOW
26.13
VOLUME
261.01K
TURNOVER
--
52 WEEK HIGH
28.74
52 WEEK LOW
10.52
MARKET CAP
1.82B
P/E (TTM)
-66.0382
1D
5D
1M
3M
1Y
5Y
Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network(R) (NCCN) Guidelines for Prostate Cancer
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical c...
GlobeNewswire · 09/13 12:09
Lantheus Announces Addition Of PSMA PET Imaging Agent To National Comprehensive Cancer Network (NCCN) Guidelines For Prostate Cancer
Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence
Benzinga · 09/13 12:04
BRIEF-Lantheus, Reflexion Report Development And Commercialization Collaboration
reuters.com · 09/13 11:36
Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting
Highlights Piflufolastat F 18’s Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer Identified Regional Lymph Node and/or Distant Metastases in 26.9% of Patients Prior to Definitive Therapy NORTH BILLERI...
GlobeNewswire · 09/10 12:30
Lantheus Holdings to Present at Upcoming Investor Conferences
NORTH BILLERICA, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence...
GlobeNewswire · 09/02 12:00
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
Zacks.com · 08/20 10:20
Insider Trends: Insider Extends 90-Day Selling Trend at Lantheus Holdings
MT Newswires · 08/12 16:45
Return on Capital Employed Overview: Lantheus Holdings
After pulling data from Benzinga Pro it seems like during Q2, Lantheus Holdings (NASDAQ:LNTH) brought in sales totaling $101.06 million. However, earnings decreased 7559.89%, resulting in a loss of $26.78 million.
Benzinga · 08/04 15:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LNTH. Analyze the recent business situations of Lantheus Hldg through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LNTH stock price target is 32.00 with a high estimate of 34.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 328
Institutional Holdings: 69.70M
% Owned: 103.10%
Shares Outstanding: 67.60M
TypeInstitutionsShares
Increased
67
7.05M
New
47
4.08M
Decreased
48
1.92M
Sold Out
19
6.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Brian Markison
President/Chief Executive Officer/Director
Mary Heino
Chief Financial Officer/Treasurer
Robert Marshall
Senior Vice President/General Counsel
Daniel Niedzwiecki
Senior Vice President
Etienne Montagut
Senior Vice President
Carol Walker
Vice President
Linda Lennox
Other
Paul Blanchfield
Other
Istvan Molnar
Independent Director
Gerard Ber
Independent Director
Samuel Leno
Independent Director
Heinz Maeusli
Independent Director
Julie Mchugh
Independent Director
Gary Pruden
Independent Director
James Thrall
No Data
About LNTH
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.

Webull offers kinds of Lantheus Holdings Inc stock information, including NASDAQ:LNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LNTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LNTH stock methods without spending real money on the virtual paper trading platform.